Elizabeth Weise, U.S.A. TODAY
Published 5: 28 p.m. ET July 22, 2020| Upgraded 8: 10 p.m. ET July 22, 2020
CLOSE
The Trump administration will pay Pfizer almost $2 billion for a December shipment of 100 million dosages of a COVID-19 vaccine the pharmaceutical company is establishing. (July 22).
AP Domestic
Pfizer and BioNTech revealed a $1.95 billion handle the federal government for pre-purchase of 100 million dosages of their speculative vaccine prospect.
The companies plan to start final Stage 2 testing and Phase 3 scientific trials by the end of the month, according to a press release Wednesday.
They stated they intend to start the regulative approval procedure to get a vaccine licensed by the Fda as early as October.
The release stated the U.S. federal government will pay the business upon the receipt of the first 100 million dosages after FDA permission or approval. It was not clear whether the payment would be made if the vaccine were not authorized by the FDA. Pfizer did not immediately react to a request for explanation.
The arrangement provides the United States an alternative to purchase an additional 500 million doses.
Americans will get the vaccine free of charge, “constant with the U.S. federal government’s commitment free of charge gain access to for COVID-19 vaccines,” the release stated.
Pfizer, a U.S.-based business, and its partner BioNTech, a German business, expect to manufacture approximately 100 million dosages worldwide by the end of 2020 and possibly more than 1.3 billion dosages by the end of 2021.
The contract is between the companies and Operation Lightning speed, a White House-led task force working to speed up development of COVID-19 vaccines and treatments.
Pfizer chose not to look for federal financing for development of its COVID-19 vaccine research, and this is the first monetary transaction between the United States and the companies for a COVID-19 vaccine
Pfizer-BioNTech is evaluating at least four experimental COVID-19 vaccines. The agreement is for the most advanced of these, BNT162 b1. It, and among the others, BNT162 b2, got Fast lane designation from the FDA on July 13 based upon initial data from early phase scientific trials taking place in the USA and Germany.
Pfizer will invest more than $1 billion in advancement, scaling and production. ” We are bearing all the threat in developing and producing our COVID vaccine,” a Pfizer spokeswoman stated by means of email Wednesday.
Operation Warp Speed also cut a $1.2 billion handle AstraZeneca, a British-Swedish business, for 300 million doses of its prospect vaccine, ought to it prove reliable and be licensed.
More: At least 2 pharmaceutical companies assure cost effective COVID-19 vaccines during the pandemic
In both offers, any vaccines that don’t make the cut will be ruined.
By pre-purchasing possible vaccine, the government is attempting to line up a huge number of dosages that can be offered as soon as it makes it through the FDA’s regulative approval procedure.
” Expanding Operation Lightning speed’s varied portfolio by adding a vaccine from Pfizer and BioNTech increases the odds that we will have a safe, efficient vaccine as soon as the end of this year,” stated Health and Human Provider Secretary Alex Azar.
Check Out or Share this story: https://www.usatoday.com/story/news/health/2020/07/22/ us-pays-1-95- billion-100- million-doses-pfizer-covid-19- vaccine/5489964002/
Comments
Post a Comment